Relmada Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Relmada Therapeutics is a clinical-stage biotechnology company focused on research and development rather than commercial sales. Its pipeline centers on NDV-01, a sustained-release intravesical formulation of gemcitabine and docetaxel for high-grade non-muscle invasive bladder cancer, and sepranolone, a neurosteroid epimer targeting compulsion-related disorders. The company has no approved products, active customer base, commercial distribution network or product revenue. If its candidates secure regulatory approval, potential revenue channels include direct product sales, licensing arrangements and strategic commercial partnerships. Relmada may build specialized commercial capabilities or rely on larger pharmaceutical partners for distribution. Sources: 0001213900-26-086151#Business
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Following a comprehensive strategic review in late 2024 and early 2025, Relmada terminated its legacy esmethadone and psilocybin programs. The company redirected its resources toward late-stage, de-risked assets in oncology and rare CNS disorders.
Expected impact: Mitigates clinical development risk, establishes a diversified pipeline with multiple registrational pathways, and targets high-value indications with significant unmet medical needs.
Developing NDV-01, a novel sustained-release intravesical formulation of gemcitabine and docetaxel, for two distinct indications: high-risk second-line BCG-unresponsive NMIBC and intermediate-risk adjuvant NMIBC.
Expected impact: Aims to establish a best-in-class, bladder-sparing therapeutic option for patients who have failed first-line therapies, addressing a market of approximately 5,000 patients annually in the U.S..
Advancing sepranolone, a novel neurosteroid epimer of allopregnanolone, into clinical trials for compulsivity-related disorders, starting with a Phase 2 study in Prader-Willi syndrome (PWS).
Expected impact: Addresses a rare genetic disorder affecting 350,000–400,000 people globally, targeting compulsive behaviors such as hyperphagia.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquired the asset sepranolone, a novel neurosteroid epimer of allopregnanolone, to expand Relmada's pipeline into rare CNS and compulsivity-related disorders. The transaction aligns with Relmada's mission to address difficult-to-treat CNS disorders and leverage its core drug development competencies.
Financial impact: The asset purchase was completed for an upfront payment of EUR 3 million (approximately USD 3.25 million).
Strategic Partnerships
Secured exclusive worldwide rights (excluding Israel, India, and South Africa) to NDV-01, a novel sustained-release intravesical formulation of gemcitabine and docetaxel for the treatment of non-muscle invasive bladder cancer (NMIBC) [2.1.3]. This partnership forms the cornerstone of Relmada's oncology pipeline.
Terms: Relmada paid an upfront license fee of $3.5 million and issued 3,017,420 restricted shares of common stock (representing 10% of outstanding shares at the time). The agreement includes up to $105 million in development/regulatory milestones, up to $95 million in commercial milestones, and a 3% royalty on net sales in the licensed territory.